Acta Biomaterialia

Acta Biomaterialia (Acta Biomater.) is a biomaterials journal published by Elsevier on behalf of Acta Materialia, Inc. Founded in 2005, it is the sister title of Acta Materialia and Scripta Materialia, concentrates on hypothesis-driven biomaterials research, appears eighteen times a year and had a 2025 impact factor of 10.4.《生物材料学报》（Acta Biomaterialia'，缩写 Acta Biomater.''）是爱思唯尔代表Acta Materialia，Inc.'''出版的生物材料学期刊，2005 年创刊，是《材料学报》与《材料快报》的姊妹刊。该刊以假设驱动的生物材料研究为主，每年十八期，二〇二五年影响因子为 10.4。

Scope

The journal's editorial stance is that a paper should be driven by a hypothesis rather than by trial and error among materials: it must state a clear assumption about how a material and a living system interact and test it by experiment or model, rather than list the characterisation of yet another material. Coverage runs from design to preclinical evaluation, and concentrates on:本刊的取稿立场是「以假设驱动而非以材料试错驱动」：一篇论文应当提出关于材料与生物体如何相互作用的明确假设，并以实验或模型加以检验，而不是罗列一组材料的表征结果。收文范围覆盖生物材料从设计到临床前评价的全过程，重点包括：

• Hypothesis-driven design: materials designed from a biological mechanism, with controlled experiments testing whether the design assumption holds.假设驱动的材料设计： 依据生物学机制设计材料，并以对照实验检验设计假设是否成立。

• Surface science and biocompatibility: protein adsorption and conformational change, cell interactions with material surfaces, blood compatibility and immune response.表面科学与生物相容性： 蛋白吸附与构象变化、细胞与材料表面的相互作用、血液相容性与免疫反应。

• Mechanical characterisation and multiscale modelling: mechanical matching between implant and tissue, degradation and fatigue, and modelling from the molecular to the organ scale.力学表征与多尺度建模： 植入物与组织的力学匹配、降解与疲劳行为、从分子到器官尺度的建模。

• Molecular and statistical modelling: molecular dynamics and statistical mechanics, computational screening in the manner of the materials genome, and quantitative structure-property relations.分子与统计建模： 分子动力学与统计力学方法、材料基因组式的计算筛选、结构与性能关系的定量描述。

• Structural biology and characterisation: microstructural analysis of biomaterials, in situ and real-time characterisation, and advances in imaging and spectroscopic method.结构生物学与表征方法： 生物材料的微观结构解析、原位与实时表征、成像与谱学方法学进展。

• Functional processing and screening: surface functionalisation and patterning, scaffolds and additive manufacturing, and high-throughput or chip-based materials for genomic and proteomic screening.功能化加工与筛查： 表面功能化与图案化、支架与增材制造、高通量与芯片式的基因组或蛋白组筛查材料。

The journal is hybrid: authors may pay an article processing charge to publish gold open access. It publishes no acceptance rate, and the publisher gives only timing indicators for review and production.本刊为混合出版模式，作者可选择支付文章处理费以金色开放获取发表；期刊不公布录用比例，官方仅给出审稿与出版的时效性指标。^[1]

History

• Founding (2005): volume 1, issue 1 appeared in January 2005 under the auspices of Acta Materialia, Inc. as an extension of the Acta Materialia family into biomaterials, with William R. Wagner of the University of Pittsburgh as founding editor-in-chief.创刊（2005年）： 2005 年 1 月出版第 1 卷第 1 期，由Acta Materialia，Inc.出资创办，作为《材料学报》系列在生物材料方向的延伸，创刊主编为（William R. Wagner，匹兹堡大学）。^[2]

• Ownership and sponsorship: the title is owned by Acta Materialia, Inc., to which the two materials societies ASM International and TMS appoint governors and contribute sponsorship, while publication has been carried by Elsevier throughout with no change of publisher since the launch.主办与赞助结构： 本刊由Acta Materialia，Inc.持有，两个材料学会 ——（ASM International）与（TMS）—— 向该机构派出理事并参与赞助，出版事务一直由爱思唯尔承担，创刊以来未发生出版方变更。^[2]

• Increase in frequency (2015): the journal was monthly at first and moved to eighteen issues a year from 2015, in step with the expansion of the Acta Materialia family, a direct reflection of growing submissions in biomaterials.刊期加密（2015年）： 创刊时为月刊，2015 年起加密至每年十八期，与《材料学报》系列的扩版同步，是生物材料方向投稿量增长的直接反映。^[3]

• Metric standing: the impact factor rose from 6.383 in 2017 to 10.4 in 2025, with a publisher CiteScore of 17.7, keeping the journal among the leading titles at the biomaterials-materials science interface. It is indexed in the Science Citation Index Expanded and Scopus.指标水平： 影响因子自 2017 年的 6.383 升至 2025 年的 10.4，官方同期引用分数为 17.7，长期居生物材料与材料科学交叉刊物前列；本刊被科学引文索引扩展版与 Scopus 收录。^[1]

Editors

The journal has been led since its founding by a single long-serving scholar, working with a board divided by discipline that includes materials scientists alongside clinicians and biologists, a composition that underpins the hypothesis-driven editorial line.本刊自创刊起即由同一位学者长期主持，编辑架构为一名主编加一支按学科分工的编委队伍，编委中既有材料科学家也有临床与生物学家，这种构成与「假设驱动」的取稿立场互为支撑。^[2]

• Present editor-in-chief (since the 2005 launch): William R. Wagner has held the chair since the journal was founded. He is a bioengineering and surgery scholar at the University of Pittsburgh working in tissue engineering and regenerative medicine, and is the only editor-in-chief the journal has had in its first two decades.现任主编（2005年创刊起任）： （William R. Wagner）自创刊起担任主编，学术身份为匹兹堡大学生物工程与外科学的学者，研究方向为组织工程与再生医学，是本刊创刊二十年间唯一一位主编。^[2]

• Composition of the board: the board is organised by biocompatibility, mechanics, surface science, drug delivery and clinical medicine, and two governors appointed by the sponsoring societies take part in the journal's governance, keeping it tied to the materials society system.编委构成： 编委会按生物相容性、力学、表面科学、药物递送与临床医学等方向分设编委，两名由赞助学会派出的理事参与期刊治理，保证刊物与材料学会体系的联系。^[2]

• Open access policy: the journal is hybrid and the gold open access article processing charge is 4,100 US dollars. The publisher publishes neither an acceptance rate nor a time to first decision, and the author guide describes only the review workflow and its timetable.开放获取政策： 本刊为混合出版，金色开放获取的文章处理费为四千一百美元；出版方未公布录用比例与首决时长，作者指南只说明审稿流程与时限安排。^[1]